Article Versions Notes

Aquila G, Regin Y, Murgia X, Salomone F, Casiraghi C, Catozzi C, Scalera E, Storti M, Stretti F, Aquino G, et al. Daily Intraperitoneal Administration of Rosiglitazone Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia. Pharmaceutics. 2022; 14(7):1507. https://doi.org/10.3390/pharmaceutics14071507

Aquila, Giorgio, Yannick Regin, Xabier Murgia, Fabrizio Salomone, Costanza Casiraghi, Chiara Catozzi, Enrica Scalera, Matteo Storti, Francesca Stretti, Giancarlo Aquino, and et al. 2022. "Daily Intraperitoneal Administration of Rosiglitazone Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia" Pharmaceutics 14, no. 7: 1507. https://doi.org/10.3390/pharmaceutics14071507

Aquila, G., Regin, Y., Murgia, X., Salomone, F., Casiraghi, C., Catozzi, C., Scalera, E., Storti, M., Stretti, F., Aquino, G., Cavatorta, G., Volta, R., Di Pasquale, C., Amato, C., Bignami, F., Amidani, D., Pioselli, B., Sgarbi, E., Ronchi, P., ... Toelen, J. (2022). Daily Intraperitoneal Administration of Rosiglitazone Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia. Pharmaceutics, 14(7), 1507. https://doi.org/10.3390/pharmaceutics14071507